What is the clinical evidence from this study?

Study design: Case Report. Population: Severe congestive heart failure associated with renal failure (n=1). Intervention: Continuous intravenous infusion of bumetanide. Primary outcome: Urine output and symptomatic relief.

January 1, 2016Journal of Integrative CardiologyOpen Access

Novelty of continuous intravenous infusion of bumetanide in severe congestive heart failure associated with renal failure

View Full Paper

Ask AI

Bookmark

Key result

Continuous intravenous infusion of bumetanide produced significant diuresis and symptomatic relief of shortness of breath in a patient with severe congestive heart failure and stage 5 chronic kidney disease.

Why the study?

Does continuous intravenous infusion of bumetanide improve symptoms and renal function in patients with severe congestive heart failure and advanced chronic kidney disease?

Population

n=1, 81-year-old white female with severe congestive heart failure and chronic kidney disease stage 5.

Design

Case_report

Follow-up

5 days of infusion, with an office follow-up at…

Authors

AMAnil K. MandalL V Prasad Eye Institute

Discussion

Member takes

Implication

Hypothesis-generating for continuous diuretic use in cardiorenal syndrome; prospective trials needed before clinical adoption.

Study Design

Type

Case Report (n=1)

Structured PICO

Does continuous intravenous infusion of bumetanide improve symptoms and renal function in patients with severe congestive heart failure and advanced chronic kidney disease?

Population

An 81-year-old female with severe congestive heart failure and stage 5 chronic kidney disease treated with continuous intravenous bumetanide infusion.

Intervention

Continuous intravenous infusion of bumetanide (24 mg dissolved in 500 ml saline, delivered at 21 ml/hour or approximately 1 mg/h) for 72 to 96 hours.

Outcome

Symptomatic relief of shortness of breath, urine output, and improvement of renal function (eGFR).surrogate

Continuous intravenous infusion of bumetanide may provide symptomatic relief and improve renal function in patients with severe congestive heart failure and advanced chronic kidney disease.

Limitations

Single case report limits generalizability.
Cause and effect relationship between bumetanide infusion and improvement in renal function is poorly understood.
Requires vigilant care to monitor fluid balance and electrolytes to prevent hypovolemia and electrolyte imbalances.
Cause and effect relationship between bumetanide infusion and improvement in renal function and extent of diuresis is poorly understood

Cite This Study

Anil K. Mandal (2016) conducted a case report in Severe congestive heart failure associated with renal failure (n=1). Continuous intravenous infusion of bumetanide was evaluated on Urine output and symptomatic relief. Continuous intravenous infusion of bumetanide produced significant diuresis and symptomatic relief of shortness of breath in a patient with severe congestive heart failure and stage 5 chronic kidney disease.

synapsesocial.com/papers/6a75da05d17bc701ee16265d https://doi.org/10.15761/jic.1000186

View Full Paper

Ask AI

Bookmark

Novelty of continuous intravenous infusion of bumetanide in severe congestive heart failure associated with renal failure

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Novelty of continuous intravenous infusion of bumetanide in severe congestive heart failure associated with renal failure

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider